(AOF) – Spineguard announces that its consolidated turnover is down 30% in the fourth quarter of 2023 compared to the fourth quarter of 2022 at 1.10 million euros, and by 23% over the entire financial year at 4.31 million euros. The company specializing in real-time surgical guidance for the placement of bone implants adds that its cash position as of December 31, 2023 amounts to €3.9 million, so it now has a horizon of cash flow until 2025.
In the United States, fourth-quarter revenue fell 28% in dollars to $734,000 due to the cessation of the activity of WishBone Medical, which had the exclusive distribution of SpineGuard products in American pediatric orthopedic hospitals. .
In the rest of the world, sales increased by 11% for products in the fourth quarter and by 22% for the whole year, marked by good growth in Europe as well as in Latin America, and includes a large order in China.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.